CENTANY Drug Patent Profile

Which patents cover Centany, and when can generic versions of Centany launch?

Centany is a drug marketed by Padagis Us and is included in one NDA.

The generic ingredient in CENTANY is mupirocin. There are sixteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mupirocin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Centany

A generic version of CENTANY was approved as mupirocin by PADAGIS ISRAEL on November 7^th, 2003.

Summary for CENTANY

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CENTANY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Padagis Us	CENTANY	mupirocin	OINTMENT;TOPICAL	050788-001	Dec 4, 2002		DISCN	No	No

International Patents for CENTANY

See the table below for patents covering CENTANY around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2165723
Canada	2259764	COMPOSITIONS PHARMACEUTIQUES RENFERMANT DE LA MUPIROCINE (PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN)
Germany	69900561
Israel	123143	PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN

CENTANY Market Analysis and Financial Projection

Last updated: February 9, 2026

What Is CENTANY and Its Market Position?

Centany (product name for bactroban) is a topical antibiotic containing mupirocin. It targets bacterial infections, primarily those caused by methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis. Approved by the FDA, it is prescribed for impetigo, nasal carriage of MRSA, and skin infections.

The drug has an established niche primarily in hospital settings and dermatology clinics. Its use in eradicating MRSA nasal carriage enhances its relevance amidst rising antibiotic resistance concerns.

What Are the Key Market and Revenue Drivers for CENTANY?

• Market Size: The global topical antibiotics market was valued at approximately $3.2 billion in 2022 and is projected to grow at a CAGR of 4% through 2028. Centany’s segment, focusing on resistant bacterial infections, accounts for an estimated 15% of this.

• Incidence of Target Conditions: Impetigo affects millions annually in the U.S., with about 2-4 million cases per year. MRSA nasal carriage prevalence varies from 20-30% in hospitals and community settings, underpinning ongoing demand.

• Prescriptions and Usage Trends: The U.S. prescriptions for mupirocin (Centany) have increased modestly, with approximately 1.2 million prescriptions in 2022. The rise mirrors heightened awareness of antibiotic stewardship and infection control practices.

• Competitive Landscape: Other topical agents like retapamulin and fusidic acid exist but target narrower indications. Resistance development to mupirocin is emerging but remains manageable with infection control initiatives.

What Are the Patent and Regulatory Considerations?

• Patent Status: The original patent for mupirocin expired around 2003. Recent formulations or delivery methods could hold additional patent protection. No recent patents preventing generic entry are active as of 2022.

• Regulatory Pathways: FDA approval granted in 1987. No significant regulatory hurdles are anticipated for extensions or new formulations unless new indications or delivery systems are introduced.

How Do R&D and Commercial Strategies Impact Investment?

• Line Extensions: Potential exists for developing combination topical agents or new delivery systems, which could extend product lifecycle.

• New Indications: Expanding into decolonization protocols for MRSA in healthcare settings could broaden usage.

• Market Penetration: Increasing adoption in outpatient settings and globally could boost revenues.

• Generic Competition: Entry of generics post-2003 has resulted in pricing pressures, reducing profit margins. However, branded versions or formulations with patent protection might sustain premiums.

What Is the Financial Outlook?

Given the mature status, Centany’s revenue is stable but limited by competition and patent expiry. The overall market growth suggests gradual revenue increases if market share is maintained or expanded. Profit margins are likely restricted by generic competition and pricing pressures, emphasizing the importance of potential new formulations or indications.

• Market Share: Estimated at 50-60% of mupirocin prescriptions in the U.S., subject to competitive shifts.

• Pricing Dynamics: Reduced over the last decade, with average retail price around $250-$350 per tube for branded mupirocin (per GoodRx data).

• Revenue Projections: With stable prescription volumes, revenue growth may be limited to 1-3% annually unless new indications or markets are unlocked.

What Are Investment Risks?

• Generic Competition: Eroding market share and margins as patents expire.

• Resistance Development: Increased mupirocin resistance could diminish efficacy, impacting prescribing patterns.

• Regulatory Changes: Stricter infection control policies or drug approval delays can impact future sales.

• Market Penetration Challenges: Difficulties expanding into new geographies or clinical settings.

Summary Table

Aspect	Details
Market Size	$3.2 billion global topical antibiotics (2022)
CAGR	4% (2023–2028)
Key Indications	Impetigo, MRSA decolonization, skin infections
Prescription Volume	~1.2 million in the US (2022)
Patent Status	Expired (2003); no recent patent protection for formulations
Competition	Generic mupirocin products; limited branded competitors
Revenue Trends	Stable but limited; potential growth via new indications/formulations
Pricing	$250–$350 per tube (branded), pressure from generics
Investment Outlook	Moderate; depends on innovation, new indication development, and market expansion

Key Takeaways

• Centany operates within a mature, minimal-growth segment primarily driven by infection control needs.
• Patent expirations and generic entry significantly limit revenue upside.
• Growth opportunities exist through expanding indications (e.g., decolonization protocols), formulation innovation, and international market penetration.
• Resistance trends and regulatory factors pose ongoing risks.

FAQs

1. What are the main factors influencing Centany’s market share?
Prescription volumes, resistance patterns, and competition from generics primarily influence market share. Patent protections or new indications can temporarily boost market positioning.

2. Could resistance to mupirocin impact the drug’s future?
Yes. Growing mupirocin resistance may lead clinicians to seek alternative therapies, reducing prescribing and revenue.

3. Are there opportunities for R&D investment in Centany?
Developing new formulations, combination therapies, or expanding approved indications (such as MRSA decolonization protocols) could extend the product’s lifecycle.

4. How does the competitive landscape affect investment?
Generic entry drives down prices and profit margins, challenging profitability for branded versions. Innovative formulations or protected markets are necessary for sustained margins.

5. What role do regulatory policies play in Centany's future prospects?
Regulations around antibiotic use and infection control can influence prescribing behaviors. No imminent regulatory barriers are expected unless new uses are pursued that require approval.

---

Citations
[1] Market data derived from Global Market Insights (2022); prescription estimates from IQVIA (2022); pricing information from GoodRx (2022); patent status from USPTO records (expired 2003).